<DOC>
	<DOCNO>NCT00139282</DOCNO>
	<brief_summary>Age-Related Macular Degeneration ( AMD ) degenerative eye disease retina cause progressive loss central vision . AMD lead cause blindness among adult age 50 old Western world . AMD present two different type : `` dry '' severe `` wet '' form . Wet AMD cause growth abnormal blood vessel macula . Squalamine lactate investigational drug may prevent growth abnormal blood vessel . This study evaluate safety efficacy Squalamine lactate treatment AMD patient , exact number determine base data sponsor 's ongoing Phase 2 trial . The trial objective evaluate safety efficacy two dos Squalamine lactate Injection administer intravenous infusion weekly 4 week follow maintenance dos every 4 week week 104 compare safety efficacy control group .</brief_summary>
	<brief_title>A Safety Efficacy Study Squalamine Lactate Injection ( MSI-1256F ) `` Wet '' Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Squalamine</mesh_term>
	<criteria>Patients diagnosis `` wet '' agerelated macular degeneration Prior treatment `` wet '' agerelated macular degeneration affect eye past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>wet AMD</keyword>
	<keyword>macular degeneration</keyword>
</DOC>